Accelerated system in Japan regulatory

Advantages of Orphan Drug Designation(ODD) and SAKIGAKE designation are shown. ODD is benefit designation and ODD is highly recommended.

Normal ODD SAKIGAKE
Application and designation

NA

Anytime

Once a year
(
Oct-Nov)

Prioritized PMDA Consultation

No

Yes

Yes

PMDA Concierge

No

No

Yes

Rolling submission

No

No

Yes

Target NDA Review Period

12 months

9 months

6 months

Extension of Re-examination period
(Exclusivity)

No
(6 years)

Yes
(Max. 10 years)

Yes
(Max. 10 years)

Grant No Yes

No